ProShares Ultra Nasdaq Biotechnology (BIB) Leveraged/Inverse
$109.80
▼ -0.67 (-0.61%)
1-day change
$62.04 – $126.40
52-week range
Holdings data is not available for this fund yet.
BIB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Performance as of Oct. 2, 2026
| Period | Price return | Total return |
|---|---|---|
| 1M | ▼ -9.84% | ▼ -9.78% |
| 3M | ▲ +2.77% | ▲ +2.84% |
| 6M | ▲ +34.28% | ▲ +34.37% |
| YTD | ▲ +37.63% | ▲ +37.74% |
| 1Y | ▲ +73.21% | ▲ +73.64% |
| 3Y | ▲ +135.47% | ▲ +142.03% |
| 5Y | ▲ +20.16% | ▲ +23.54% |
| Max | ▲ +1362.31% | ▲ +1406.10% |
Volatility 1Y42.75%
Volatility 3Y41.86%
Max drawdown 3Y
-45.99%
Beta 3Y0.85
Sharpe 1Y*1.50
Total return assumes dividends are reinvested. Returns are not benchmarked against an index. * Sharpe ratio is computed with a 0% risk-free rate.
Fund flows (SEC-reported)
Last month (May 2026)
-$4.8M
Quarter ending May 2026
-$13.9M
Trailing 12 months
-$12.0M
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Full composition 267 holdings
| Name | CUSIP | Value | % | Balance | Category | Country |
|---|---|---|---|---|---|---|
| Unknown security | · | $5.4M | 7.35 | 3,524 | DE | US |
| ProShares GENIUS Money Market ETF | 74350P691 | $5.0M | 6.80 | 50,000 | OTHER | US |
| Gilead Sciences, Inc. | 375558103 | $3.4M | 4.66 | 25,542 | EC | US |
| Vertex Pharmaceuticals, Inc. | 92532F100 | $3.4M | 4.65 | 7,657 | EC | US |
| Amgen, Inc. | 031162100 | $3.3M | 4.48 | 9,803 | EC | US |
| Unknown security | · | $2.9M | 3.94 | 2,513 | DE | US |
| Unknown security | · | $2.4M | 3.26 | 2,639 | DE | US |
| Regeneron Pharmaceuticals, Inc. | 75886F107 | $2.4M | 3.21 | 3,840 | EC | US |
| Unknown security | · | $1.9M | 2.62 | 3,374 | DE | US |
| Alnylam Pharmaceuticals, Inc. | 02043Q107 | $1.5M | 2.01 | 4,904 | EC | US |
| Revolution Medicines, Inc. | 76155X100 | $1.2M | 1.57 | 7,326 | EC | US |
| Biogen, Inc. | 09062X103 | $1.1M | 1.44 | 5,425 | EC | US |
| Repurchase Agreement | · | $945K | 1.28 | 944,611 | RA | US |
| Illumina, Inc. | 452327109 | $921K | 1.25 | 5,653 | EC | US |
| United Therapeutics Corp. | 91307C102 | $902K | 1.22 | 1,620 | EC | US |
| Royalty Pharma plc | · | $883K | 1.20 | 15,837 | EC | GB |
| Argenx SE | 04016X101 | $878K | 1.19 | 1,050 | EC | NL |
| Unknown security | · | $871K | 1.18 | 4,232 | DE | US |
| Insmed, Inc. | 457669307 | $852K | 1.16 | 7,968 | EC | US |
| Roivant Sciences Ltd. | · | $794K | 1.08 | 26,460 | EC | BM |
| Incyte Corp. | 45337C102 | $712K | 0.97 | 7,359 | EC | US |
| Viatris, Inc. | 92556V106 | $692K | 0.94 | 42,565 | EC | US |
| Moderna, Inc. | 60770K107 | $689K | 0.94 | 14,600 | EC | US |
| Guardant Health, Inc. | 40131M109 | $629K | 0.85 | 4,850 | EC | US |
| INVESCO GOVT AND AGCY LEX | 825252885 | $598K | 0.81 | 598,016 | STIV | US |
| Repurchase Agreement | · | $594K | 0.81 | 594,435 | RA | US |
| Neurocrine Biosciences, Inc. | 64125C109 | $588K | 0.80 | 3,712 | EC | US |
| Jazz Pharmaceuticals plc | · | $538K | 0.73 | 2,275 | EC | IE |
| Ascendis Pharma A/S | · | $510K | 0.69 | 2,276 | EC | DK |
| Summit Therapeutics, Inc. | 86627T108 | $503K | 0.68 | 28,664 | EC | US |
| Exelixis, Inc. | 30161Q104 | $485K | 0.66 | 9,600 | EC | US |
| Bridgebio Pharma, Inc. | 10806X102 | $475K | 0.64 | 7,167 | EC | US |
| Medpace Holdings, Inc. | 58506Q109 | $470K | 0.64 | 1,051 | EC | US |
| Ionis Pharmaceuticals, Inc. | 462222100 | $467K | 0.63 | 6,109 | EC | US |
| Repurchase Agreement | · | $446K | 0.61 | 445,826 | RA | US |
| Axsome Therapeutics, Inc. | 05464T104 | $443K | 0.60 | 1,890 | EC | US |
| Madrigal Pharmaceuticals, Inc. | 558868105 | $421K | 0.57 | 847 | EC | US |
| BioMarin Pharmaceutical, Inc. | 09061G101 | $407K | 0.55 | 7,110 | EC | US |
| BioNTech SE | 09075V102 | $404K | 0.55 | 4,213 | EC | DE |
| Arrowhead Pharmaceuticals, Inc. | 04280A100 | $403K | 0.55 | 5,178 | EC | US |
| Sanofi SA | 80105N105 | $395K | 0.54 | 9,047 | EC | FR |
| Praxis Precision Medicines, Inc. | 74006W207 | $360K | 0.49 | 1,029 | EC | US |
| Cytokinetics, Inc. | 23282W605 | $349K | 0.47 | 4,553 | EC | US |
| BeOne Medicines Ltd. | 07725L102 | $340K | 0.46 | 1,181 | EC | CH |
| Krystal Biotech, Inc. | 501147102 | $334K | 0.45 | 1,080 | EC | US |
| Repurchase Agreement | · | $327K | 0.44 | 326,939 | RA | US |
| Tempus AI, Inc. | 88023B103 | $324K | 0.44 | 6,424 | EC | US |
| Abivax SA | 00370M103 | $301K | 0.41 | 2,271 | EC | FR |
| Nuvalent, Inc. | 670703107 | $299K | 0.41 | 2,705 | EC | US |
| Halozyme Therapeutics, Inc. | 40637H109 | $290K | 0.39 | 4,364 | EC | US |
Dividends 13 payments
0.20%TTM yield
$0.23TTM payout / share
Quarterly
(est.)
| Ex-date | Amount / share |
|---|---|
| Sept. 23, 2026 | $0.0830 |
| March 25, 2026 | $0.0070 |
| Dec. 24, 2025 | $0.1350 |
| Sept. 24, 2025 | $0.1810 |
| June 25, 2025 | $0.1710 |
| March 26, 2025 | $0.1310 |
| Dec. 23, 2024 | $0.3960 |
| Sept. 25, 2024 | $0.1530 |
| June 26, 2024 | $0.2650 |
| March 20, 2024 | $0.0400 |
| Dec. 20, 2023 | $0.0380 |
| Dec. 22, 2022 | $0.0200 |
| Sept. 21, 2010 | $0.0110 |
Institutional owners (13F) 22 filers
Institutions that report holding this ETF in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| Institution | Value | % of tracked 13F | Shares | Type | As of |
|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $785,973 | 21.94% | 7,802 | Shares | June 30, 2026 |
| Capital Investment Advisors, LLC | $599,013 | 16.72% | 5,946 | Shares | June 30, 2026 |
| Kaizen Financial Strategies | $535,554 | 14.95% | 5,315 | Shares | June 30, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $413,034 | 11.53% | 4,100 | Call option | June 30, 2026 |
| Palumbo Wealth Management LLC | $402,960 | 11.25% | 4,000 | Shares | June 30, 2026 |
| CITADEL ADVISORS LLC | $302,220 | 8.44% | 3,000 | Call option | June 30, 2026 |
| Jump Financial, LLC | $257,189 | 7.18% | 2,553 | Shares | June 30, 2026 |
| TOTH FINANCIAL ADVISORY CORP | $102,957 | 2.87% | 1,022 | Shares | June 30, 2026 |
| FRANKLIN RESOURCES INC | $70,115 | 1.96% | 696 | Shares | June 30, 2026 |
| PNC Financial Services Group, Inc. | $50,370 | 1.41% | 500 | Shares | June 30, 2026 |
| Ashton Thomas Private Wealth, LLC | $37,576 | 1.05% | 373 | Shares | June 30, 2026 |
| Truvestments Capital LLC | $12,593 | 0.35% | 125 | Shares | June 30, 2026 |
| Axiom Investment Management LLC | $5,037 | 0.14% | 50 | Shares | June 30, 2026 |
| Qube Research & Technologies Ltd | $4,936 | 0.14% | 49 | Shares | June 30, 2026 |
| SIMPLEX TRADING, LLC | $1,309 | 0.04% | 13 | Shares | June 30, 2026 |
| CHASE INVESTMENT COUNSEL CORP | $241 | 0.01% | 2,400 | Shares | June 30, 2026 |
| Rockefeller Capital Management L.P. | $201 | 0.01% | 2 | Shares | June 30, 2026 |
| MORGAN STANLEY | $131 | 0.00% | 1 | Shares | June 30, 2026 |
| UBS Group AG | $101 | 0.00% | 1 | Shares | June 30, 2026 |
| WELLS FARGO & COMPANY/MN | $65 | 0.00% | 1 | Shares | June 30, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | $20 | 0.00% | 198 | Shares | June 30, 2026 |
| ROYAL BANK OF CANADA | $0 | 0.00% | 1 | Shares | June 30, 2026 |